Hematologic effects of flt3 ligand in vivo in miceBRASEL, K; MCKENNA, H. J; MORRISSEY, P. J et al.Blood. 1996, Vol 88, Num 6, pp 2004-2012, issn 0006-4971Article

FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. CommentaryBROWN, P; SMALL, D; TALLEN, G et al.European journal of cancer (1990). 2004, Vol 40, Num 5, pp 707-724, issn 0959-8049, 18 p.Article

Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatmentLEE KIM SWEE; BOSCO, Nabil; MALISSEN, Bernard et al.Blood. 2009, Vol 113, Num 25, pp 6277-6287, issn 0006-4971, 11 p.Article

FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA VaccinesKREITER, Sebastian; DIKEN, Mustafa; SELMI, Abderraouf et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 19, pp 6132-6142, issn 0008-5472, 11 p.Article

Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted TumorsCURRAN, Michael A; ALLISON, James P.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 19, pp 7747-7755, issn 0008-5472, 9 p.Article

Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agentsFURUICHI, Yoshiyuki; GOI, Kumiko; XIAOCHUN ZHANG et al.Cancer research (Baltimore). 2007, Vol 67, Num 20, pp 9852-9861, issn 0008-5472, 10 p.Article

Multi-level effects of fit 3 ligand on human hematopoiesis : expansion of putative stem cells proliferation of granulomonocytic progenitors/monocytic precursorsGABBIANELLI, M; PELOSI, E; PESCHLE, C et al.Blood. 1995, Vol 86, Num 5, pp 1661-1670, issn 0006-4971Article

Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges : Myeloid biologySTERNBERG, David W; LICHT, Jonathan D.Current opinion in hematology. 2005, Vol 12, Num 1, pp 7-13, issn 1065-6251, 7 p.Article

Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemiaCOOLS, Jan; MENTENS, Nicole; FURET, Pascal et al.Cancer research (Baltimore). 2004, Vol 64, Num 18, pp 6385-6389, issn 0008-5472, 5 p.Article

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemiaABU-DUHIER, F. M; GOODEVE, A. C; WILSON, G. A et al.British journal of haematology. 2001, Vol 113, Num 4, pp 983-988, issn 0007-1048Article

Expression of Flt3-ligand by the endothelial cellSOLANILLA, A; GROSSET, C; LEMERCIER, C et al.Leukemia. 2000, Vol 14, Num 1, pp 153-162, issn 0887-6924Article

Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferationKHARAZI, Shabnam; MEAD, Adam J; RECKZEH, Kristian et al.Blood. 2011, Vol 118, Num 13, pp 3613-3621, issn 0006-4971, 9 p.Article

Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3GEORGE, Prince; BALI, Purva; MOSCINSKI, Lynn et al.Cancer research (Baltimore). 2004, Vol 64, Num 10, pp 3645-3652, issn 0008-5472, 8 p.Article

FLT3 mutations and leukaemiaPANACIOTIS; KOTTARIDIS, D; GALE, Rosemary E et al.British journal of haematology. 2003, Vol 122, Num 4, pp 523-538, issn 0007-1048, 16 p.Article

Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuliJEFFORD, Michael; SCHNURR, Max; PARENTE, Phil et al.Blood. 2003, Vol 102, Num 5, pp 1753-1763, issn 0006-4971, 11 p.Article

Mechanism of flt3 ligand expression in bone marrow failure : Translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesisCHKLOVSKAIA, E; JANSEN, W; NISSEN, C et al.Blood. 1999, Vol 93, Num 8, pp 2595-2604, issn 0006-4971Article

The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasisKINGSTON, Dior; SCHMID, Michael A; ONAI, Nobuyuki et al.Blood. 2009, Vol 114, Num 4, pp 835-843, issn 0006-4971, 9 p.Article

Crucial role of FLT3 ligand in immune reconstitution after bone marrow transplantation and high-dose chemotherapyBUZA-VIDAS, Natalija; MIN CHENG; DUARTE, Sara et al.Blood. 2007, Vol 110, Num 1, pp 424-432, issn 0006-4971, 9 p.Article

CCR and CC chemokine expression in relation to Flt3 ligand-induced renal dendritic cell mobilizationCOATES, P. Toby H; COLVIN, Bridget L; RANGANATHAN, Anju et al.Kidney international. 2004, Vol 66, Num 5, pp 1907-1917, issn 0085-2538, 11 p.Article

FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impactAU, Wing Y; FUNG, Alvin; CHIM, Chor S et al.British journal of haematology. 2004, Vol 125, Num 4, pp 463-469, issn 0007-1048, 7 p.Article

FLT3 mutations in childhood acute lymphoblastic leukemiaARMSTRONG, Scott A; MABON, Meghann E; SILVERMAN, Lewis B et al.Blood. 2004, Vol 103, Num 9, pp 3544-3546, issn 0006-4971, 3 p.Article

FLT3 mutations in myeloid sarcomaANSARI-LARI, M. Ali; YANG, Ching-Fen; TINAWI-ALJUNDI, Rima et al.British journal of haematology. 2004, Vol 126, Num 6, pp 785-791, issn 0007-1048, 7 p.Article

Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancerHIGANO, Celestia S; VOGELZANG, Nicholas J; SOSMAN, Jeffrey A et al.Clinical cancer research. 2004, Vol 10, Num 4, pp 1219-1225, issn 1078-0432, 7 p.Article

Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with Mutant FLT-3BALI, Purva; GEORGE, Prince; MOSCINSKI, Lynn et al.Clinical cancer research. 2004, Vol 10, Num 15, pp 4991-4997, issn 1078-0432, 7 p.Article

Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitutionFRY, Terry J; SINHA, Manoj; MILLIRON, Matthew et al.Blood. 2004, Vol 104, Num 9, pp 2794-2800, issn 0006-4971, 7 p.Article